1-3 of 3
Mohammad Azam
Close
Save search
Sort by
Journal Articles

Enhanced MAPK signaling induced by CSF3R mutants confers dependence to DUSP1 for leukemic transformation

Free
Meenu Kesarwani, Zachary Kincaid, Mohammad Azhar, Mohammad Azam
Journal: Blood Advances
Blood Adv (2024) 8 (11): 2765–2776.
https://doi.org/10.1182/bloodadvances.2023010830
Published: 2024
Includes: Supplemental data
Journal Articles

Rational polypharmacological targeting of FLT3, JAK2, ABL, and ERK1 suppresses the adaptive resistance to FLT3 inhibitors in AML

Free
Mohammad Azhar, Zachary Kincaid, Meenu Kesarwani, Jacob Menke, Joshua Schwieterman, Sekhu Ansari, Angela Reaves, Arhama Ahmed, Rammsha Shehzad, Areeba Khan, Nuha Syed, Noor Amir, Mark Wunderlich, Tahir Latif, William Seibel, Mohammad Azam
Journal: Blood Advances
Blood Adv (2023) 7 (8): 1460–1476.
https://doi.org/10.1182/bloodadvances.2022007486
Published: 2023
Includes: Supplemental data
Journal Articles

Momelotinib is a highly potent inhibitor of FLT3-mutant AML

Free
Mohammad Azhar, Zachary Kincaid, Meenu Kesarwani, Arhama Ahmed, Mark Wunderlich, Tahir Latif, Daniel Starczynowski, Mohammad Azam
Journal: Blood Advances
Blood Adv (2022) 6 (4): 1186–1192.
https://doi.org/10.1182/bloodadvances.2021004611
Published: 2022
Includes: Supplemental data